Nisa Investment Advisors LLC Boosts Holdings in AbbVie Inc. $ABBV

Nisa Investment Advisors LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 0.9% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 477,960 shares of the company’s stock after purchasing an additional 4,315 shares during the period. AbbVie makes up about 0.4% of Nisa Investment Advisors LLC’s holdings, making the stock its 27th biggest holding. Nisa Investment Advisors LLC’s holdings in AbbVie were worth $110,667,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. G&S Capital LLC boosted its position in AbbVie by 0.5% during the third quarter. G&S Capital LLC now owns 18,847 shares of the company’s stock valued at $4,364,000 after buying an additional 93 shares during the period. Next Level Private LLC lifted its stake in shares of AbbVie by 1.6% in the 3rd quarter. Next Level Private LLC now owns 3,274 shares of the company’s stock valued at $754,000 after acquiring an additional 50 shares during the last quarter. Dock Street Asset Management Inc. bought a new stake in shares of AbbVie in the 3rd quarter valued at about $245,000. Duncker Streett & Co. Inc. boosted its holdings in AbbVie by 17.7% during the 3rd quarter. Duncker Streett & Co. Inc. now owns 71,277 shares of the company’s stock valued at $16,503,000 after acquiring an additional 10,721 shares during the period. Finally, Legacy Wealth Management LLC MS bought a new position in AbbVie during the 3rd quarter worth approximately $205,000. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline progress: AbbVie advanced its Phase 2 icalcaprant trial in depression, which keeps a potential late-stage CNS asset on the radar and preserves upside if clinical data are positive. Read More.
• Positive Sentiment: New oncology program: AbbVie launched a first‑in‑human ABBV‑901 ovarian cancer trial, expanding its oncology pipeline and creating a longer-term growth optionality. Read More.
• Positive Sentiment: Real‑world evidence readouts: Post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped up, which can support label, payer conversations and uptake in key markets. Read More. Read More.
• Positive Sentiment: Analyst support and dividend narrative: Berenberg upgraded to a Buy and investor commentary emphasizing AbbVie’s reliable dividend/ income profile may underpin longer‑term demand from income-focused funds. Read More. Read More.
• Neutral Sentiment: Event calendar: AbbVie scheduled its full‑year and Q4 2025 earnings release and call for Feb. 4 — an upcoming catalyst where management can clarify guidance drivers. Read More.
• Negative Sentiment: Guidance nudged below consensus: AbbVie updated Q4 2025 EPS to $3.320–3.360 (vs. street ~3.360) and FY 2025 to $10.610–10.650 (vs. ~10.650), a small miss that removes near‑term upside expectations. (Company guidance release)
• Negative Sentiment: One‑time accounting hit: Management flagged IPR&D and related expenses that will negatively impact Q4 EPS, pressuring reported profitability this quarter. Read More.
• Negative Sentiment: M&A rumor volatility: Reports the company was in talks to buy Revolution Medicines briefly lifted both stocks; AbbVie subsequently denied talks, a reversal that likely contributed to intraday selling pressure. Read More. Read More.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Guggenheim raised their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Morgan Stanley upped their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Finally, DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Stock Down 3.9%

AbbVie stock opened at $224.22 on Friday. The company has a market capitalization of $396.28 billion, a P/E ratio of 169.86, a PEG ratio of 0.98 and a beta of 0.36. The stock’s 50 day moving average is $226.55 and its 200 day moving average is $214.86. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.